Psyence Biomedical (PBM) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Psyence Biomedical and Filament Health Corp. have amended their existing License Agreement, including the termination of their Commercial Term Sheet, effective as of the date the amendment is signed. The amendments include provisions for Filament to continue stability testing to potentially extend the shelf-life of their PEX010 5mg dosage and provide an alternative product for Psyence’s Phase IIb study if needed. This strategic move could influence the companies’ stock performance as investors watch the potential impact on Psyence’s upcoming clinical trials and commercialization efforts.
For further insights into PBM stock, check out TipRanks’ Stock Analysis page.